David Avigan

18.3k total citations · 2 hit papers
208 papers, 7.5k citations indexed

About

David Avigan is a scholar working on Immunology, Hematology and Oncology. According to data from OpenAlex, David Avigan has authored 208 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Immunology, 104 papers in Hematology and 100 papers in Oncology. Recurrent topics in David Avigan's work include Immunotherapy and Immune Responses (75 papers), Multiple Myeloma Research and Treatments (65 papers) and CAR-T cell therapy research (51 papers). David Avigan is often cited by papers focused on Immunotherapy and Immune Responses (75 papers), Multiple Myeloma Research and Treatments (65 papers) and CAR-T cell therapy research (51 papers). David Avigan collaborates with scholars based in United States, Israel and Canada. David Avigan's co-authors include Jacalyn Rosenblatt, Donald Küfe, Robin Joyce, Pier Paolo Pandolfi, Keisuke Ito, Zekui Wu, Baldev Vasir, Jianlin Gong, Kenneth C. Anderson and Ugo Ala and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

David Avigan

205 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

2011 809 citations Philippe Armand, Robin Joyce et al. profile →
A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance

2012 556 citations Keisuke Ito, David Avigan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Avigan United States	42	3.7k	3.0k	2.9k	2.6k	702	208	7.5k
Qing Yi United States	54	4.9k 1.3×	3.8k 1.2×	3.6k 1.2×	1.8k 0.7×	1.7k 2.4×	197	9.8k
Matthias Theobald Germany	37	2.4k 0.7×	1.7k 0.6×	2.2k 0.8×	2.4k 0.9×	276 0.4×	145	5.9k
Pier Francesco Ferrucci Italy	37	1.7k 0.4×	2.9k 1.0×	3.7k 1.3×	1.2k 0.5×	409 0.6×	141	6.2k
Martine Amiot France	49	1.8k 0.5×	4.8k 1.6×	2.7k 0.9×	2.9k 1.1×	704 1.0×	131	7.9k
Markus Y. Mapara United States	35	1.6k 0.4×	2.5k 0.8×	1.8k 0.6×	1.5k 0.6×	649 0.9×	174	5.0k
Frederic I. Preffer United States	43	2.3k 0.6×	2.0k 0.6×	2.0k 0.7×	1.6k 0.6×	620 0.9×	112	7.0k
Shinsuke Iida Japan	46	2.7k 0.7×	3.0k 1.0×	2.7k 0.9×	2.2k 0.9×	490 0.7×	331	7.8k
Hideto Tamura Japan	25	5.0k 1.3×	1.2k 0.4×	5.4k 1.9×	1.1k 0.4×	425 0.6×	88	8.0k
Torben Plesner Denmark	38	1.4k 0.4×	2.2k 0.7×	2.4k 0.8×	3.2k 1.2×	507 0.7×	169	5.6k
David B. Miklos United States	37	2.6k 0.7×	1.5k 0.5×	2.2k 0.8×	2.1k 0.8×	336 0.5×	224	6.5k

Countries citing papers authored by David Avigan

Since Specialization

Citations

This map shows the geographic impact of David Avigan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Avigan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Avigan more than expected).

Fields of papers citing papers by David Avigan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Avigan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Avigan. The network helps show where David Avigan may publish in the future.

Co-authorship network of co-authors of David Avigan

This figure shows the co-authorship network connecting the top 25 collaborators of David Avigan. A scholar is included among the top collaborators of David Avigan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Avigan. David Avigan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cheloni, Giulia, Dimitra Karagkouni, Yered Pita-Juárez, et al.. (2025). Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire. Nature Communications. 16(1). 4819–4819.

Frigault, Matthew J., Jacalyn Rosenblatt, Binod Dhakal, et al.. (2024). Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Results From at Least 1-Year Follow-Up in All Patients. Clinical Lymphoma Myeloma & Leukemia. 24. S237–S237. 2 indexed citations

Avigan, David, et al.. (2023). Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy. International Journal of Hematology. 117(5). 652–659. 13 indexed citations

Huang, Ling, Dina Stroopinsky, Giulia Cheloni, et al.. (2022). Personalized tumor vaccine for pancreatic cancer. Cancer Immunology Immunotherapy. 72(2). 301–313. 11 indexed citations

Kuruvilla, John, Philippe Armand, Mehdi Hamadani, et al.. (2022). Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study. Leukemia & lymphoma. 64(1). 130–139. 12 indexed citations

Anastasiadou, Eleni, Anita G. Seto, Xuan Beatty, et al.. (2020). Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo. Clinical Cancer Research. 27(4). 1139–1149. 110 indexed citations

Ribrag, Vincent, David Avigan, Damian J. Green, et al.. (2019). Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE‐013. British Journal of Haematology. 186(3). e41–e44. 63 indexed citations

Jain, Salvia, Abigail Washington, Rebecca Karp Leaf, et al.. (2017). Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. Molecular Cancer Therapeutics. 16(10). 2304–2314. 10 indexed citations

Weinstock, Matthew, Jacalyn Rosenblatt, & David Avigan. (2017). Dendritic Cell Therapies for Hematologic Malignancies. Molecular Therapy — Methods & Clinical Development. 5. 66–75. 42 indexed citations

10.

Sadelain, Michel, David Avigan, Priscilla K. Brastianos, et al.. (2015). Collaboration in Cancer Trials (October 26–27, 2015). The Oncologist. 20(S2). S1–S8. 2 indexed citations

11.

Jain, Salvia, Dina Stroopinsky, Yin Li, et al.. (2015). Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 126(3). 354–362. 28 indexed citations

12.

DeAngelo, Daniel J., Kristen E. Stevenson, Donna Neuberg, et al.. (2015). A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial. Blood. 126(23). 80–80. 37 indexed citations

13.

Stroopinsky, Dina, Jacalyn Rosenblatt, Keisuke Ito, et al.. (2013). MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells. Cancer Research. 73(17). 5569–5579. 41 indexed citations

14.

Raina, Deepak, Rehan Ahmad, Maya Datt Joshi, et al.. (2009). Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells. Cancer Research. 69(12). 5133–5141. 125 indexed citations

15.

Vasir, Baldev, Zekui Wu, Keith Crawford, et al.. (2008). Fusions of Dendritic Cells with Breast Carcinoma Stimulate the Expansion of Regulatory T Cells while Concomitant Exposure to IL-12, CpG Oligodeoxynucleotides, and Anti-CD3/CD28 Promotes the Expansion of Activated Tumor Reactive Cells. The Journal of Immunology. 181(1). 808–821. 41 indexed citations

16.

Kawano, Takeshi, Masaki Ito, Deepak Raina, et al.. (2007). MUC1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells. Cancer Research. 67(24). 11576–11584. 34 indexed citations

17.

Vasir, Baldev, David Avigan, Zekui Wu, et al.. (2005). Dendritic Cells Induce MUC1 Expression and Polarization on Human T Cells by an IL-7-Dependent Mechanism. The Journal of Immunology. 174(4). 2376–2386. 26 indexed citations

18.

Exley, Mark A., Syed Muhammad Tahir, Olivia Cheng, et al.. (2001). Cutting Edge: A Major Fraction of Human Bone Marrow Lymphocytes Are Th2-Like CD1d-Reactive T Cells That Can Suppress Mixed Lymphocyte Responses. The Journal of Immunology. 167(10). 5531–5534. 127 indexed citations

19.

Gong, Jianlin, Najmosama Nikrui, Dongshu Chen, et al.. (2000). Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity. The Journal of Immunology. 165(3). 1705–1711. 184 indexed citations

20.

Avigan, David, Paul G. Richardson, Anthony Elias, et al.. (1998). Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors. Cancer. 83(3). 409–414. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact